Lactate orchestrates communication between tumor and microenvironment
Pancreatic ductal adenocarcinoma, one of medicine's most stubborn adversaries, has long resisted treatment not merely through brute biology but through a kind of metabolic cunning—and a new review in Current Molecular Pharmacology illuminates how lactate, a molecule the body generates routinely, has been co-opted by tumors as a tool of growth, immune evasion, and epigenetic manipulation. The process of lactylation—in which lactate chemically modifies proteins to alter their behavior—emerges as a central mechanism by which pancreatic cancer reshapes its own neighborhood into a fortress hostile to treatment. Researchers are now developing inhibitors that target this system, though the distance between laboratory promise and clinical reality remains a measure of how deeply this disease has learned to adapt.
- Pancreatic cancer cells exploit lactate not as waste but as a weapon, using it to fuel growth, silence immune defenses, and chemically rewrite the behavior of proteins through a process called lactylation.
- Lactylation drives macrophages toward a tumor-protective state and exhausts the T cells that would otherwise hunt cancer cells, effectively converting the tumor's surroundings into an immunosuppressive stronghold.
- Inhibitors targeting lactate-producing enzymes and transport proteins show early promise in the lab, especially when paired with chemotherapy or immunotherapy, but pancreatic tumors' dense physical barriers and metabolic flexibility complicate the path forward.
- Systemic toxicity looms as a serious obstacle—blocking lactate metabolism does not discriminate between cancerous and healthy tissue, demanding far more precise therapeutic tools.
- Researchers are calling for spatial transcriptomics and conditional knockout models to map tumor heterogeneity with enough resolution to design site-specific interventions that spare the body while disrupting the tumor's metabolic conversation.
Pancreatic cancer cells have learned to turn a common metabolic molecule against the body that produces it. Lactate, long regarded as little more than cellular exhaust, functions in pancreatic ductal adenocarcinoma as a fuel source, a signaling agent, and a chemical catalyst for epigenetic change. A new review in Current Molecular Pharmacology traces this metabolic conspiracy in careful detail, offering researchers a clearer map of how one of the deadliest known cancers sustains itself and evades treatment.
The process begins with oncogenic KRAS mutations, a hallmark of the disease, which reprogram cellular metabolism and flood the tumor microenvironment with lactate. Within the dense, fibrous tissue surrounding pancreatic tumors, lactate becomes a kind of currency—used by cancer cells as fuel, as a growth-promoting signal, and as raw material for lactylation, a modification in which lactate molecules attach to proteins and alter their function. Enzymes including p300 and CBP catalyze these changes on histone and non-histone proteins alike, promoting tumor proliferation and spread.
The immune consequences are equally serious. Lactylation steers macrophages toward a state in which they protect rather than attack tumors, while T cells become progressively exhausted and lose their capacity to recognize cancer. Corresponding author Dr. Zhe Liu frames lactylation not as an internal feedback loop but as a spatial signaling system—one that orchestrates the relationship between cancer cells and the stromal tissue surrounding them, transforming the tumor's microenvironment into an immunosuppressive fortress.
Therapeutic strategies are taking shape in response. Inhibitors of lactate dehydrogenase A and monocarboxylate transporters have shown encouraging results in preclinical settings, particularly in combination with existing chemotherapy or immunotherapy regimens. But the obstacles are formidable: the desmoplastic barrier surrounding pancreatic tumors blocks drug delivery, tumors can switch metabolic fuel sources when one pathway is disrupted, and systemic inhibition of lactate metabolism risks harming healthy tissue throughout the body.
The review's authors argue that progress will require more granular tools—spatial transcriptomics to identify which cells are driving which processes, and conditional knockout models to capture tumor heterogeneity at a finer scale. These approaches could make it possible to design inhibitors that act precisely within the tumor itself, leaving the rest of the body's lactate metabolism intact. For a disease that claims the lives of most patients within five years of diagnosis, that precision may be the difference between a promising mechanism and a genuine therapy.
Pancreatic cancer cells have learned to weaponize a molecule that the body produces every day. Lactate, long dismissed as mere metabolic waste, turns out to be far more sinister—a fuel that feeds tumors, a signal that recruits the immune system to stand down, and a chemical key that unlocks epigenetic changes that make cancer cells harder to kill. A new review in Current Molecular Pharmacology maps this metabolic conspiracy in detail, offering researchers a clearer picture of how one of the deadliest cancers sustains itself and evades treatment.
The story begins with a fundamental shift in how cancer cells eat. When oncogenic KRAS mutations take hold—a hallmark of pancreatic ductal adenocarcinoma—cells reprogram their metabolism in ways that flood the tumor microenvironment with lactate. This is not accidental. The dense, fibrous tissue surrounding pancreatic tumors creates a unique ecosystem where lactate becomes currency. Cancer cells use it as fuel. They use it to send signals that activate pathways favoring tumor growth. And they use it as raw material for a process called lactylation, in which lactate molecules attach to proteins and change how those proteins behave.
Lactylation is where the real trouble begins. Enzymes like p300 and CBP catalyze these modifications on histone and non-histone proteins, altering their function in ways that promote tumor proliferation and spread. The process also reshapes the immune landscape. Lactate-driven lactylation pushes immune cells called macrophages toward an M2 phenotype—a state where they support tumor growth rather than attack it. Meanwhile, T cells become exhausted, their ability to recognize and kill cancer cells worn down. Dr. Zhe Liu, the corresponding author of the review, emphasizes that lactylation operates as more than an internal feedback loop. It functions as a spatial signaling system, orchestrating communication between cancer cells and the stromal cells that surround them, turning the tumor's neighborhood into an immunosuppressive fortress.
Therapeutic strategies are emerging. Researchers are testing inhibitors of lactate dehydrogenase A, an enzyme that produces lactate, and monocarboxylate transporters, which ferry lactate in and out of cells. Early results in the laboratory are encouraging, particularly when these drugs are combined with chemotherapy or immunotherapy. But the path from bench to bedside is steep. Pancreatic tumors are notoriously difficult to treat, wrapped in a dense desmoplastic barrier that blocks drugs from reaching cancer cells. Tumors also exhibit metabolic plasticity—the ability to switch fuel sources when one pathway is blocked. And systemic toxicity remains a concern; inhibiting lactate metabolism affects healthy cells too.
The authors call for a more sophisticated approach. Future research should employ spatial transcriptomics to map which cells are doing what, and conditional knockout models to understand tumor heterogeneity at a granular level. These tools could enable the design of site-specific inhibitors that target lactate metabolism precisely where it matters most—within the tumor itself—while sparing the rest of the body. For a disease that kills the vast majority of patients within five years of diagnosis, this kind of precision matters. The review provides a foundation for understanding how lactate orchestrates pancreatic cancer's survival, and in doing so, it points toward a new generation of therapies that might finally disrupt the conversation between tumor and microenvironment.
Notable Quotes
Lactylation is not merely an intracellular feedback mechanism but a spatial signaling mediator that orchestrates multicellular communication within the dense stroma of pancreatic cancer— Dr. Zhe Liu, corresponding author
The Hearth Conversation Another angle on the story
Why does lactate matter so much in pancreatic cancer specifically? Isn't lactate produced in every tumor?
It is, but pancreatic cancer creates a uniquely dense, fibrous environment where lactate accumulates to extraordinary levels. That stroma becomes a lactate-soaked ecosystem. The cancer cells have essentially learned to thrive in their own waste.
So lactate isn't just fuel—it's also a signal?
Exactly. It's a messenger. It tells immune cells to stand down. It modifies proteins in ways that make cancer cells more aggressive. It's doing multiple jobs at once, which is why blocking it is so complicated.
What happens when you try to block lactate production?
In the lab, tumors slow down. But in the body, cancer cells are clever. They switch to other fuel sources. And you risk harming healthy cells that also depend on lactate metabolism. It's not a simple on-off switch.
The review mentions spatial transcriptomics as a future direction. What would that actually tell us?
It would show us which cells are producing lactate, which are consuming it, and what's happening in the space between them. Right now we're looking at averages. Spatial transcriptomics would let us see the actual geography of the tumor's conversation with itself.
Is there any reason to be optimistic about treating this?
The preclinical results are real. Combining lactate inhibitors with existing therapies shows promise. But pancreatic cancer has always been a disease that teaches humility. We need to be smarter about where and how we intervene.